Relapsing autoimmune pancreatitis type 1: case report
Authors:
Alena Ondrejková 1; Bohuslav Kianička 1; Hana Nechutová 1; Lukáš Hruška 2; Ivo Novotný 3; Miroslav Souček 1
Authors‘ workplace:
Gastroenterologické oddělení II. interní kliniky LF MU a FN u sv. Anny v Brně
1; Klinika zobrazovacích metod LF MU a FN u sv. Anny v Brně
2; Gastroenterologické oddělení MOÚ, Brno
3
Published in:
Vnitř Lék 2017; 63(4): 277-283
Category:
Case Reports
Overview
Autoimmune pancreatitis (AIP) is a rare form of chronic pancreatitis, classified into 2 subtypes – AIP type 1 and AIP type 2. We present a case of a 31-years-old female admitted to our institution with upper abdominal pain and obstructive jaundice. Endoscopic retrograde cholangiopancreatoscopy (ERCP) revealed stenosis of intrapancreatic distal bile duct. Diffuse parenchymal enlargement and typical features of AIP were shown by computed tomography (CT) and endoscopic ultrasonography (EUS). The patient´s serum IgG4 was elevated at 3.8 g/l (range 0.08–1.4 g/l). She was diagnosed with AIP type 1 and treated with prednisone (initial dose of 30 mg per day, then tapered by 5 mg/day every week). The maintenance dose of 5 mg per day was continued for 6 months. Despite clinical and radiological remission, serum levels of IgG4 remained elevated. The patient experienced disease relapse 25 months after first attack. Moreover, new finding of calcifications occured in pancreas. The relapse was managed with corticosteroids and maintenance immunosupression with azathioprin was started. Literature review on risk factor of relapse, long-term immunosupressive therapy indication and optimal follow-up of AIP type 1 patients are discussed.
Key words:
autoimmune pancreatitis type 1 – long-term follow-up – relapse – therapy
Sources
1. Shimosegawa T, Chari ST, Frulloni L et al. International consensus diagnostic criteria for autoimmune pancreatitis: guidelines of the International Association of Pancreatology. Pancreas 2011; 40(3): 352–358. Dostupné z DOI: <http://dx.doi.org/10.1097/MPA.0b013e3182142fd2>.
2. Dítě P, Novotný I, Kianička B et al. Autoimmune pancreatitis - diagnostic consensus. Vnitř Lék 2015; 61(2): 114–118.
3. Hirano K, Tada M, Isayama H et al. Long-term prognosis of autoimmune pancreatitis with and without corticosteroid treatment. Gut 2007; 56(12): 1719–1724.
4. Kim HM, Chung MJ, Chung JB. Remission and relapse of autoimmune pancreatitis: focusing on corticosteroid treatment. Pancreas 2010; 39(5): 555–560. Dostupné z DOI: <http://dx.doi.org/10.1097/MPA.0b013e3181c8b4a5>.
5. Kubota K, Watanabe S, Uchiyama T et al. Factors predictive of relapse and spontaneous remission of autoimmune pancreatitis patients treated/not treated with corticosteroids. J Gastroenterol 2011; 46(6): 834–842. Dostupné z DOI: <http://dx.doi.org/10.1007/s00535–011–0393-y>.
6. Sahani DV, Sainani NI, Deshpande V et al. Autoimmune pancreatitis: disease evolution, staging, response assessment, and CT features that predict response to corticosteroid therapy. Radiology 2009; 250(1): 118–129. Dostupné z DOI: <http://dx.doi.org/10.1148/radiol.2493080279>.
7. Maire F, Le Baleur Y, Rebours V et al. Outcome of patients with type 1 or 2 autoimmune pancreatitis. Am J Gastroenterol 2011; 106(1): 151–156. Dostupné z DOI: <http://dx.doi.org/10.1038/ajg.2010.314>.
8. Ikeura T, Miyoshi H, Shimatani M et al. Long-term outcomes of autoimmune pancreatitis. World J Gastroenterol 2016; 22(34): 7760–7766. Dostupné z DOI: <http://dx.doi.org/10.3748/wjg.v22.i34.7760>.
9. Maruyama M, Watanabe T, Kanai K et al. Autoimmune pancreatitis can develop into chronic pancreatitis. Orphanet J Rare Dis 2014; 9: 77. Dostupné z DOI: <http://dx.doi.org/10.1186/1750–1172–9-77>.
10. Takuma K, Kamisawa T, Tabata T et al. Short-term and long-term outcomes of autoimmune pancreatitis. Eur J Gastroenterol Hepatol 2011; 23(2): 146–152.
11. Kanno A, Masamune A, Okazaki K et al. Nationwide epidemiological survey of autoimmune pancreatitis in Japan in 2011. Pancreas 2015; 44(4): 535–539. Dostupné z DOI: <http://dx.doi.org/10.1097/MPA.0000000000000325>.
12. Sah RP, Chari ST. Autoimmune pancreatitis: an update on classification, diagnosis, natural history and management. Curr Gastroenterol Rep 2012; 14(2): 95–105. Dostupné z DOI: <http://dx.doi.org/10.1007/s11894–012–0246–8>.
13. Hart PA, Kamisawa T, Brugge WR et al. Long-term outcomes of autoimmune pancreatitis: a multicentre, international analysis. Gut 2013; 62(12): 1771–1776. Dostupné z DOI: <http://dx.doi.org/10.1136/gutjnl-2012–303617>.
14. Macinga P, Malušková J, Oliverius M et l. Autoimmune pancreatitis in patients resected for focal pancreatic lesion – First results. Gastroenterol Hepatol 2014; 68(4): 340–345.
15. Dite P, Novotny I, Trna J et al. Autoimmune pancreatitis. Best Pract Res Clin Gastroenterol 2008; 22(1): 131–143. Dostupné z DOI: <http://dx.doi.org/10.1016/j.bpg.2007.10.014>.
16. Sugumar A. Diagnosis and management of autoimmune pancreatitis. Gastroenterol Clin North Am 2012; 41(1): 9–22. Dostupné z DOI: <http://dx.doi.org/10.1016/j.gtc.2011.12.008>.
17. Chari ST, Takahashi N, Levy MJ et al. A diagnostic strategy to distinguish autoimmune pancreatitis from pancreatic cancer. Clin Gastroenterol Hepatol 2009; 7(10): 1097–1103. Dostupné z DOI: <http://dx.doi.org/10.1016/j.cgh.2009.04.020>.
18. Sah RP, Chari ST. Serologic issues in IgG4-related systemic disease and autoimmune pancreatitis. Curr Opin Rheumatol 2011; 23(1): 108–113. Dostupné z DOI: <http://dx.doi.org/10.1097/BOR.0b013e3283413469>.
19. Raina A, Krasinskas AM, Greer JB et al. Serum immunoglobulin G fraction 4 levels in pancreatic cancer: elevations not associated with autoimmune pancreatitis. Arch Pathol Lab Med 2008; 132(1): 48–53. Dostupné z DOI: <http://dx.dpo.org/10.1043/1543–2165(2008)132[48:SIGFLI]2.0.CO;2>.
20. Bojková M, Dítě P, Dvořáčková J et al. Immunoglobulin G4, autoimmune pancreatitis and pancreatic cancer. Dig Dis 2015; 33(1): 86–90. Dostupné z DOI: <http://dx.doi.org/10.1159/000368337>.
21. Oseini AM, Chaiteerakij R, Shire AM et al. Utility of serum immunoglobulin G4 in distinguishing immunoglobulin G4-associated cholangitis from cholangiocarcinoma. Hepatology 2011; 54(3): 940–948. Dostupné z DOI: <http://dx.doi.org/10.1002/hep.24487>.
22. Balasubramanian G, Sugumar A, Smyrk TC et al. Demystifying seronegative autoimmune pancreatitis. Pancreatology 2012; 12(4): 289–294. Dostupné z DOI: <http://dx.doi.org/10.1016/j.pan.2012.05.003>.
23. Kubota K, Kamisawa T, Okazaki K et al. Low-dose maintenance steroid treatment could reduce the relapse rate in patients with type 1 autoimmune pancreatitis: a long-term Japanese multicenter analysis of 510 patients. J Gastroenterol 2017 Jan 6 (on-line). Dostupné z DOI: <http://dx.doi.org/10.1007/s00535–016–1302–1>.
24. Hart PA, Topazian MD, Witzig TE et al. Treatment of relapsing autoimmune pancreatitis with immunomodulators and rituximab: the Mayo Clinic experience. Gut 2013; 62(11): 1607–1615. Dostupné z DOI: <http://dx.doi.org/10.1136/gutjnl-2012–302886>.
25. Culver EL, Sadler R, Simpson D et al. Elevated Serum IgG4 Levels in Diagnosis, Treatment Response, Organ Involvement, and Relapse in a Prospective IgG4-Related Disease UK Cohort. Am J Gastroenterol 2016; 111(5): 733–743. Dostupné z DOI: <http://dx.doi.org/10.1038/ajg.2016.40>.
26. Sah RP, Chari ST, Pannala R et al. Differences in clinical profile and relapse rate of type 1 versus type 2 autoimmune pancreatitis. Gastroenterology 2010; 139(1): 140–148; quiz e12-e13. Dostupné z DOI: <http://dx.doi.org/10.1053/j.gastro.2010.03.054>.
27. Yoshida K, Toki F, Takeuchi T et al. Chronic pancreatitis caused by an autoimmune abnormality. Proposal of the concept of autoimmune pancreatitis. Dig Dis Sci 1995; 40(7): 1561–1568.
28. Yamamoto M, Takahashi H, Tabeya T et al. Risk of malignancies in IgG4-related disease. Mod Rheumatol 2012; 22(3): 414–418. Dostupné z DOI: <http://dx.dpo.org/10.1007/s10165–011–0520-x>.
Labels
Diabetology Endocrinology Internal medicineArticle was published in
Internal Medicine
2017 Issue 4
Most read in this issue
- Relapsing autoimmune pancreatitis type 1: case report
- Controversies around QALYs
- AT1 blockers – comparability with ACE inhibitors
- Novelties in the treatment of heart failure